Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?
Joachim Havla,1 Ingo Kleiter,2 Tania Kümpfel11Institute of Clinical Neuroimmunology, Medical Campus Grosshadern, Ludwig Maximilians University, Munich, 2Department of Neurology, St Josef Hospital, Ruhr University, Bochum, GermanyAbstract: Natalizumab (NAT) was the first monoclonal antibody...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Boek |
| Gepubliceerd in: |
Dove Medical Press,
2013-10-01T00:00:00Z.
|
| Onderwerpen: | |
| Online toegang: | Connect to this object online. |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
| Plaatsingsnummer: |
A1234.567 |
|---|---|
| Kopie 1 | Beschikbaar |